In the present study, we investigated whether repeated treatment with the new orally active, long acting and blood brain barrier penetrant ghrelin agonist, HM01 (Karasawa et al., 2014a), had beneficial effects on several homeostatic dysfunctions in the 6-OHDA rat PD model not treated with L-dopa. This evidence concerns the gene GHRL and Parkinson disease.